Targeting a specific protein to improve treatment for Ewing sarcoma
Dissecting and targeting PAK4 in Ewing sarcoma
This study is looking at a specific protein called PAK4 that is linked to worse outcomes in kids and young adults with Ewing sarcoma, and it aims to find new treatments that can help improve their chances of recovery.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10980926 on NIH RePORTER |
What this research studies
This research focuses on Ewing sarcoma, a type of bone cancer that primarily affects children and young adults. The study aims to investigate the role of p21-activated kinases (PAKs), particularly PAK4, which is found to be overexpressed in metastatic Ewing sarcoma and linked to poor patient outcomes. By exploring targeted therapies that inhibit PAK4, the research seeks to improve treatment options and outcomes for patients with high-risk Ewing sarcoma. The approach includes both laboratory experiments and potential pharmacological interventions to assess the effectiveness of targeting this protein.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with Ewing sarcoma, especially those with metastatic or relapsed forms of the disease.
Not a fit: Patients with non-Ewing sarcoma bone tumors or those who are not diagnosed with cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with Ewing sarcoma, particularly those with metastatic disease.
How similar studies have performed: Other research has shown promising results in targeting similar pathways in cancer treatment, indicating potential for success in this approach.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Yustein, Jason — Emory University
- Study coordinator: Yustein, Jason
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.